Envafolimab drug page Clinical trials

Trials with Envafolimab

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

9Trials
3Recruiting
1Countries
1.196Planned patients

Showing 1–7 of 7

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Recruiting Phase 2 60 patients NCT06321081

This is a non-profit phase II, open, clinical study of the combination of irinotecan plus cetuximab and envafolimab as a rechallenge regimen, in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients (according to liquid biop…

China Mar 2024 – Dec 2026 Interventional
Combined with: CetuximabIrinotecan
Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
Recruiting Phase 2 198 patients NCT05959356

The primary aim of phase II CEIL study is to evaluate the efficacy of cetuximab and envafolimab plus mFOLFOXIRI versus cetuximab plus mFOLFOX6 as first line treatment of patients with initially unresectable and previously untreated RAS/BRA…

China Nov 2023 – Dec 2028 Interventional
A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)
Not yet recruiting Phase 2 590 patients NCT06959693

This is a prospective randomized controlled Phase Ⅱ/Ⅲ Clinical study to evaluate the clinical efficacy and safety of Envafolimab combining with Cetuximab -β and mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer…

China Jun 2025 – Jun 2030 Interventional
A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer
Not yet recruiting Phase 2 42 patients NCT07000305

A study of Cetuximabβ combined with Envolimab and mFOLFOX6 in Subjects with Advanced Colorectal Cancer

China May 2025 – May 2028 Interventional
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Not yet recruiting Phase 2 72 patients NCT05969847

Patients diagnosed with locally advanced very low rectal cancer were chosen to participate in a comprehensive neoadjuvant therapy (TNT) protocol. This treatment regimen consisted of preoperative fractionated radiotherapy (5×7Gy) combined w…

China Aug 2023 – Dec 2027 Interventional
Combined with: CapecitabineOxaliplatin
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
Finished Phase 2 33 patients NCT06060704

The goal of this single-arm study is to evaluate the efficacy and safety of Envafolimab combined with Trifluridine/Tipiracil and Bevacizumab in the treatment of metastatic colorectal cancer patients who are refractory or intolerant to stan…

China Nov 2023 – Sept 2025 Interventional
Combined with: Bevacizumab
Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Finished Phase 2 55 patients NCT06014372

There exists substantial evidence suggesting that patients diagnosed with MSI-H/dMMR colorectal cancer can derive benefits from immunotherapy in the management of advanced colorectal cancer. In cases of locally advanced colorectal cancer e…

China Jul 2023 – Jul 2026 Interventional
Combined with: CapecitabineOxaliplatin

Where the recruiting trials are